Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
new york blog main
new york top stories
2
×
allergan
biotech
boehringer ingelheim
boston blog main
boston top stories
bristol-myers squibb
clinical data
eli lilly
empagliflozin
europe
europe blog main
europe top stories
fda
genfit
gilead sciences
indiana blog main
indiana top stories
intercept pharmaceuticals
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
nash
national top stories
new york
nonalcoholic steatohepatitis
obeticholic acid
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
slgt2 inhibitor
type 1 diabetes
type 2 diabetes
What
drug
marketed
2
×
approval
approved
bid
boehringer
data
diabetes
disease
eli
expand
fallen
fatty
fda
horizon
ingelheim
intercept
known
lilly
liver
medicine
medicine’s
nash
new
nonalcoholic
patients
rejects
short
steatohepatitis
track
type
Language
unset
Current search:
marketed
×
" new york top stories "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug